GH Research PLC GHRS Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$18.61 up $0.17, 0.92% at close Nov 6
Last close · Previous close $18.44
- Market cap
- At the Nov 6 close
- P/E ratio
- n/mLoss over last 12 months
- Diluted EPS
- −$1.00Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$18.61up $0.17, 0.92%Fri, Nov 6 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$18.44Nov 5
- Volume407.25KNov 5 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume337.29KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $12.04 to $31.44; now $18.61
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
GHRS beat the S&P 500 in 3 of 6 periods.
| Period | GHRS and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | GHRS: down 13.5% S&P 500: down 5.6% | GHRS trailed the S&P 500 by 7.9 percentage points Trailed |
| 3M | GHRS: down 39.3% S&P 500: down 4.1% | GHRS trailed the S&P 500 by 35.2 percentage points Trailed |
| YTD | GHRS: up 46.5% S&P 500: up 8.7% | GHRS beat the S&P 500 by 37.8 percentage points Beat |
| 1Y | GHRS: up 38.8% S&P 500: up 10.9% | GHRS beat the S&P 500 by 27.9 percentage points Beat |
| Long term | ||
| 3Y | GHRS: up 128.9% S&P 500: up 75.0% +31.8% vs +20.5% a year | GHRS beat the S&P 500 by 53.9 percentage points Beat |
| 5Y | GHRS: down 23.6% S&P 500: up 67.8% −5.2% vs +10.9% a year | GHRS trailed the S&P 500 by 91.4 percentage points Trailed |
$10,000 invested in GHRS 5 years ago (Nov 5, 2021) would be worth about $7,643 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $16,782.
GHRS beat the S&P 500 in 3 of 6 periods.
| Period | GHRS and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | GHRS: down 13.5% S&P 500: down 5.6% | GHRS trailed the S&P 500 by 7.9 percentage points Trailed |
| 3M | GHRS: down 39.3% S&P 500: down 4.3% | GHRS trailed the S&P 500 by 35.0 percentage points Trailed |
| YTD | GHRS: up 46.5% S&P 500: up 7.8% | GHRS beat the S&P 500 by 38.7 percentage points Beat |
| 1Y | GHRS: up 38.8% S&P 500: up 9.7% | GHRS beat the S&P 500 by 29.1 percentage points Beat |
| Long term | ||
| 3Y | GHRS: up 128.9% S&P 500: up 68.8% +31.8% vs +19.1% a year | GHRS beat the S&P 500 by 60.1 percentage points Beat |
| 5Y | GHRS: down 23.6% S&P 500: up 56.9% −5.2% vs +9.4% a year | GHRS trailed the S&P 500 by 80.5 percentage points Trailed |
$10,000 invested in GHRS 5 years ago (Nov 5, 2021) would be worth about $7,643 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $15,694.
All-time high
$30.64
Closing high on . Now 39.3% below that record.
Split-adjusted daily closes since Jun 25, 2021.
Stock splits
GHRS hasn’t split since its price history begins in 2021.
Valuation
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $0.00
- Net income
- −$62.27M
- Diluted EPS
- −$1.00
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q3 FY24 (Sep 30, 2024) | $0.00 | −$12.11M | −$0.23 |
| Q4 FY24 (Dec 31, 2024) | $0.00 | −$8.80M | −$0.17 |
| Q1 FY25 (Mar 31, 2025) | $0.00 | −$10.81M | −$0.19 |
| Q2 FY25 (Jun 30, 2025) | $0.00 | −$9.29M | −$0.15 |
| Q3 FY25 (Sep 30, 2025) | $0.00 | −$14.02M | −$0.23 |
| Q4 FY25 (Dec 31, 2025) | $0.00 | −$14.14M | −$0.23 |
| Q1 FY26 (Mar 31, 2026) | $0.00 | −$18.97M | −$0.31 |
| Q2 FY26 (Jun 30, 2026) | $0.00 | −$15.15M | −$0.23 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $0.00 | −$9.20M | −$0.21 |
| FY22 (Dec 31, 2022) | $0.00 | −$22.46M | −$0.43 |
| FY23 (Dec 31, 2023) | $0.00 | −$35.59M | −$0.68 |
| FY24 (Dec 31, 2024) | $0.00 | −$38.96M | −$0.75 |
| FY25 (Dec 31, 2025) | $0.00 | −$48.26M | −$0.79 |
Margins
- Gross —
- Operating —
- Net —
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$64.63MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$64.49MLast 12 months
- Capital spending$138.00KLast 12 months
Shareholder returns
- $118.04MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paidNot reportedLast 12 months
Balance sheet
- $362.65MAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$360.00KAs of Jun 30, 2026
- Net cash$362.29MAs of Jun 30, 2026
- 28.70As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.00As of Jun 30, 2026
Total debt divided by shareholders’ equity on the Jun 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- −20.9%Last 12 months
Over the last 12 months, GH Research lost money: its net loss was 20.9% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −20.1%Last 12 months
Over the last 12 months, GH Research’s net loss was 20.1% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH Research PLC's initial focus is on developing its novel and proprietary mebufotenin therapies for the treatment of patients with treatment-resistant depression (TRD). About GH001 Our lead product candidate, GH001, is formulated for mebufotenin administration via a proprietary inhalation approach. Based on the observed clinical activity in our completed phase 1/2 GH001-TRD-102 trial, where 87.5% of patients with TRD achieved ultra-rapid remission with our GH001 individualized single-day dosing regimen in the Phase 2 part of the trial, we believe that GH001 has the potential to change the way TRD is treated today. About Notation for Trial Timepoints In relation to our clinical trials we have previously referred to the day of dosing as Day 0 (D0), the day after dosing as Day 1 (D1), and the seventh day after dosing as Day 7 (D7). In this press release, and going forward, we shall refer to the day of dosing as Day 1 (D1), the day after dosing as Day 2 (D2) and the seventh day after dosing as Day 8 (D8).
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Ireland
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
GHRS news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
GHRS stock FAQ
What is GHRS stock’s price today?
GH Research (GHRS) traded at $18.61 at the close on , up $0.17 (0.92%) from the previous close of $18.44. Over the past 52 weeks it has traded between $12.04 and $31.44.
If you invested $1,000 in GHRS 5 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in GHRS on would be worth about $764 at the close on , a total return of −23.6%. The same $1,000 would be worth $1,388 if invested one year ago. Past performance doesn’t predict future returns.
What is GHRS’s P/E ratio?
GHRS’s P/E ratio isn’t meaningful right now because its earnings over the four quarters to are negative (diluted EPS of −$1.00).
What are GHRS’s earnings per share?
GHRS’s diluted earnings per share were −$1.00 over the four quarters to , compared with −$0.74 in the twelve months before. The latest quarter (Q2 FY26) brought −$0.23 per share, against −$0.15 a year earlier (how EPS works).
Does GHRS pay a dividend?
GH Research hasn’t paid a dividend in the last twelve months.
What is GHRS’s 52-week high and low?
Over the past 52 weeks GHRS has traded as low as $12.04 and as high as $31.44. At $18.61 at the close on , it is 40.8% below that high and 54.6% above the low.
What is GHRS’s all-time high?
GHRS’s highest closing price was $30.64 on , adjusted for stock splits. At $18.61 at the close on , it is 39.3% below that record.
Has GHRS stock ever split?
No. GHRS hasn’t split since its price history begins in 2021.
How has GHRS stock performed?
Including dividends and measured to the close on , GHRS has returned +46.5% so far this year and +38.8% over the past year, and −23.6% over five years (−5.2% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is GH Research in?
GH Research is in the Healthcare sector and the Biotechnology industry, and is headquartered in Ireland.
What exchange does GHRS trade on?
GH Research trades on the Nasdaq under the ticker symbol GHRS. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.